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ABSTRACT
The MexZ–MexX–MexY multidrug efflux system in Pseudomonas aeruginosa was studied to determine its
contribution to aminoglycoside resistance. Amikacin-resistant (AR) mutants were generated from
P. aeruginosa strain PAO1, and clinical isolates of P. aeruginosa were collected from cystic fibrosis
patients. The regulatory gene mexZ and the intergenic region (mexOZ) between mexZ and mexX were
investigated for mutation by PCR and DNA sequence analysis. The results showed that 14 of 15 AR
clinical isolates and one of ten laboratory mutants had at least one mutation in mexZ and ⁄ or mexOZ. To
study the effect of mexZ and mexOZ mutations, the production of MexY mRNA was investigated
quantitatively by real-time PCR. Seven of ten AR mutants (MIC 4–8 mg ⁄L) produced 8–21-fold more
MexY mRNA than PAO1. These isolates were sensitive to fluoroquinolones, carbapenems and
ceftazidime. One AR mutant (MIC 64 mg ⁄L) that produced > 200-fold more MexY mRNA than PAO1
was also resistant to fluoroquinolones, carbapenems and ceftazidime. Thirteen of 15 AR clinical isolates
produced 3.4–727-fold more MexY mRNA. No evidence was found for the aminoglycoside-modifying
enzymes 6¢-N-acetyltransferase type Ib, 4¢-O-nucleotidyltransferase type IIb or aminoglycoside 3¢-phos-
photransferase IIps in these strains. Nine AR mutants overproduced MexY without mutations in mexZ
or mexOZ, suggesting that MexXY efflux is also regulated by gene(s) other than mexZ.
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INTRODUCTION
Pseudomonas aeruginosa is an opportunistic organ-
ism involved in chronic lung infection in patients
with cystic fibrosis (CF) and is a leading cause of
nosocomial infections [1]. Such infections are
difficult to treat because of intrinsic and acquired
resistance to antibiotics, including aminoglyco-
sides, in P. aeruginosa isolates from CF patients.
Decreased outer-membrane permeability, amino-
glycoside-inactivating enzymes, ribosomal altera-
tions and several multidrug efflux systems
contribute to acquired and intrinsic resistance in
P. aeruginosa [2]. Intrinsic resistance in this organ-
ism results from reduced outer-membrane per-
meability and multidrug efflux pumps that keep
the intracellular concentration of antibiotics low
[3,4]. Over-expression of transporter molecules
results in the recognition and expulsion of a broad
range of structurally unrelated antimicrobial com-
pounds, including antibiotics, detergents, dyes
and organic solvents [5–7].
At least five efflux systems are involved in
antibiotic resistance in P. aeruginosa, namely Mex-
AB–OprM [8], MexCD–OprJ [9], MexEF–OprN
[10], MexXY [5,11] and MexJK [12]. These efflux
systems belong to the resistance-nodulation-cell
division (RND) superfamily [13]. Among these
efflux systems, MexAB–OprM and MexXY are
produced constitutively, while MexCD–OprJ,
MexEF–OprN and MexJK are involved in ac-
quired resistance to different antibiotics
[5,6,8,10,11]. However, only the MexXY efflux
pump is involved in resistance to hydrophilic
aminoglycosides in P. aeruginosa. MexY is a drug
proton anti-porter, associated with the membrane
fusion protein MexX [14], and is homologous to
Corresponding author and reprint requests: B. Wretlind,
Division of Clinical Bacteriology F82, Department of Laborat-
ory Medicine, Karolinska University Hospital Huddinge,
S-14186 Stockholm, Sweden
E-mail: bengt.wretlind@labmed.ki.se
 2004 Copyright by the European Society of Clinical Microbiology and Infectious Diseases
AcrD in Escherichia coli [15]. Elevated expression of
the mexXY (amrAB) efflux system has been found
in several impermeability-type aminoglycoside-
resistant isolates of P. aeruginosa, and has been
described as the predominant cause of aminogly-
coside resistance in isolates from CF lungs [16–19].
Since the mexXY system does not have a gene
for an outer-membrane protein downstream of
mexY, it has been suggested that the MexXY efflux
system shares the OprM channel with MexAB
[5,11]. The expression of MexXY is under negative
regulation by another protein, MexZ, which is
encoded by a gene that is transcribed divergently
and located 263 bp upstream of mexX. MexZ
contains a helix–turn–helix motif at its N-terminal
end that is thought to be a DNA-binding domain
[5]. Deletion of mexXY from wild-type P. aerugi-
nosa isolates increases their susceptibility to gen-
tamicin, tetracycline and erythromycin [5]. The
pump is also inducible by its substrate antibiotics,
e.g., tetracycline and gentamicin [20], and is able
to pump out fluoroquinolones, macrolides and
carbapenems [21,22].
The present study investigated the role and
regulation of the mexXY operon in aminoglyco-
side-resistant clinical isolates of P. aeruginosa from
CF patients, as well as in laboratory mutants of
strain PAO1. Mutations were found within the
repressor-coding region and the region between
the MexZ- and MexX-encoding genes, and the
effect of these mutations on the expression of
mexY, mexZ and oprM was investigated. Since it
has been suggested that the porin gene oprD is
negatively co-regulated with mexXY [23], the
expression of oprD was also determined.
MATERIALS AND METHODS
Bacterial strains and mutants
Laboratory-derived mutants of P. aeruginosa strain PAO1
(B. W. Holloway, Monash University, Melbourne, Australia)
were selected on IsoSensitest agar (Oxoid, Basingstoke, UK)
plates containing amikacin (Sigma, St Louis, MO, USA) 4, 8, 16
and 32 mg ⁄L. Each plate was inoculated with 108 CFU of
strain PAO1 and incubated for 48 h. Clinical isolates of
P. aeruginosa were collected from CF patients attending the CF
Centre at Huddinge University Hospital (Stockholm, Sweden)
during 2001. Fifteen aminoglycoside-resistant and five sensitive
isolates from sputum, each of which came from a different
patient, were included in this study. Strain PAO1 was used as a
control. The reference strains for aminoglycoside-modifying
enzyme AAC(6¢)-Ib were P. aeruginosa strains 101 ⁄ 1477, PPV-97
and VR143 ⁄ 97 and Acinetobacter baumannii strain AC 54 ⁄ 97
(kindly supplied by G. M. Rossolini, University of Siena, Italy).
MIC determination
MICs of amikacin, tobramycin, netilmicin, gentamicin, ceftaz-
idime, meropenem, imipenem, norfloxacin, ciprofloxacin and
tetracycline were determined by Etest (AB Biodisk, Solna,
Sweden) according to the manufacturer’s instructions on
Mueller–Hinton agar (Oxoid). The MIC was defined as the
lowest antibiotic concentration that inhibited visible growth
following incubation at 37C for 18 h.
PCR and DNA sequencing
Nucleotide sequence information for primer design (Table 1)
was obtained from the Pseudomonas genome project (http://
www.pseudomonas.com). Preparation of chromosomal DNA
and subsequent PCRs to amplify a 594-bp fragment of the
mexZ gene and a 263-bp fragment of mexOZ located between
the mexZ and mexX genes was done according to the method of
Jalal et al. [24]. PCRs were done as described previously [24],
except that the annealing temperatures were 61C for mexZ
and 60C for mexOZ. PCR products were sequenced by
capillary electrophoresis on an ABI Prism 310 (Applied
Biosytems, Foster City, CA, USA). Plasmids and chromosomal
DNA from all clinical and mutant strains were analysed by
PCR for the presence of aminoglycoside-modifying enzyme
genes aac(6¢)-Ib (GenBank accession no. X60321) [25], ant(4¢)-IIb
[26] and aph(3¢)-IIps [27]. Plasmids were extracted with
QIAquick Spin Minipreps (Qiagen, Hilden, Germany). The
primer sequence for aph(3¢)-IIps was as described by Torres
et al. [27]. PCRs were done as described previously [24], except
that annealing temperatures were 58C for ant(4¢)-IIb and
aac(6¢)-Ia, and 56C for aph(3¢)-IIps.
RNA purification and synthesis of cDNA
Bacterial cells were grown in broth to the logarithmic phase
and harvested by centrifugation at 2000 g for 10 min at 4C.
The supernatant was discarded, and the cell pellet was
resuspended in 500 lL 50 mM Tris buffer, pH 8.0. The cell
density was adjusted to c. 1.5 · 108 cells ⁄mL by comparison
with a 0.5· McFarland standard. The cell suspension was kept
on ice throughout these procedures. Aliquots (200 lL) of this
Table 1. Primers used in this study
Primer name Sequence
mexB-1a (22 mer) 5¢-CAA GGG CGT CGG TGA CTT CCA G-3¢
mexB-2a (22 mer) 5¢-ACC TGG CAA CCG TCG GGA TTG A-3¢
mexZ-1 (20 mer) 5¢-AAG GGC GTG GGC ACC ACT GC-3¢
mexZ-2 (20 mer) 5¢-GGA CCA GCG CAG GCA CCT GA-3¢
mexZ-1a (20 mer) 5¢-AGG TCT GCC TGG CGA TGT GC-3¢
mexZ-2a (20 mer) 5¢-AGC GTT GCC CCT GCT TCT CG- 3¢
mexOZ-1 (20 mer) 5¢-CAG CGA GCC GGT CCA TTG GA-3¢
mexOZ-2 (20 mer) 5¢-TCG CAC ATC GCC AGG CAG AC-3¢
mexY-1a (21 mer) 5¢-GGA CCA CGC CGA AAC CGA ACG-3¢
mexY-2a (21 mer) 5¢-CGC CGC AAC TGA CCC GCT ACA-3¢
oprD-1a (21 mer) 5¢-CGA CCT GCT GCT CCG CAA CTA-3¢
oprD-2a (21 mer) 5¢-TTG CAT CTC GCC CCA CTT CAG-3¢
oprM-1a (20 mer) 5¢-CGG ATC GGC GTG GAC GGT AG-3¢
oprM-2a (20 mer) 5¢-GGT GCC CAG GGT GTC CTT GG-3¢
rpsL-1a (21 mer) 5¢-GCT GCA AAA CTG CCC GCA ACG-3¢
rpsL-2a (21 mer) 5¢-ACC CGA GGT GTC CAG CGA ACC-3¢
aac(6¢)-IbU 5¢-GAG TGG GGC GGA GAA GA-3¢
aac(6¢)-IbL 5¢-CCC AAG CCT TTG CCC AGT TG-3¢
ant(4¢)-IibU 5¢-TTA CCG CAC CTG GAT AGA GC-3¢
ant(4¢)-IibU 5¢-GAT GGG GAT CAA CAA TGT CG-3¢
aPrimers used in real-time PCR.
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cell suspension were used to isolate total RNA according to the
manufacturer’s protocol for the High Pure RNA Isolation Kit
(Roche Diagnostics, Mannheim, Germany), to give a final
elution volume of RNA of 100 lL, which was then stored at
) 70C until use. The RNA concentration was measured by
spectrophotometry at 260 nm (Ultrospec 3000; Amersham
Pharmacia Biotech, Little Chalfont, UK). A 2-lL (0.5 lg ⁄lL)
sample of total RNA was used to synthesise cDNA by reverse
transcription according to the manufacturer’s procedure for
the 1st Standard cDNA Synthesis Kit for reverse transcription
PCR (Roche). The resulting cDNA was stored at ) 20C until
used for real-time PCR.
Real-time PCR
A mastermix containing 4 mM MgCl2 and 0.15 lM each
primer was prepared on ice with a LightCycler-FastStart
DNA Master SYBR Green I kit (Roche). cDNA (2 lL) was
added to 18 lL of mastermix in a pre-cooled LightCycler
capillary tube (Roche). Amplification conditions (LightCycler;
Roche) for real-time PCR comprised initial denaturation for
10 min at 95C, followed by 45 cycles of 95C for 60 s, 62C for
5 s and 72C for 16 s. The temperature transition rate was
20C ⁄ s. Melting curve analysis was done at 95C for 60 s, 67C
for 60 s and 95C for 0 s with temperature transition rates of
20C ⁄ s for the first two segments, and 0.1C ⁄ s for the third
segment. The same annealing temperature and other condi-
tions were used to determine the cDNA levels of mRNA for
MexZ, MexY, MexB, OprM and OprD. cDNA for the ribosomal
protein RpsL (ribosomal protein S12) was used as a control in
the real-time PCR assay, with the relative amounts of cDNA
for MexZ, MexY, MexB, OprM and OprD being calculated
according to a standard curve for real-time PCR efficiency
(data not shown), where 3.4 cycles caused a ten-fold increase in
cDNA. Ratios of > 3-fold the levels found in PAO1 were
considered significant.
RESULTS
Isolation of P. aeruginosa mutants
Eight single colonies were isolated from each
plate and their MICs were determined. The
mutants investigated were chosen from several
independent experiments. The frequency of ami-
kacin-resistant mutants was c. 10)7.
MIC determination
The antibiotic susceptibilities of the mutants and
clinical isolates of P. aeruginosa are shown in
Tables 2 and 3, respectively. Amikacin MICs for
the mutants were 4–64 mg ⁄L, compared with
2 mg ⁄L for the wild-type. All mutants showed
elevated MICs of amikacin (2–32-fold) and neti-
lmicin (2–16-fold). There were no significant
increases in the MICs of tobramycin and gentam-
icin. All mutants, except AK67, were susceptible
to ceftazidime, meropenem, imipenem, norfloxa-
cin, ciprofloxacin and tetracycline. Mutant AK67
(amikacin MIC 64 mg ⁄L) was also resistant to
carbapenems (imipenem and meropenem) and
fluoroquinolones (norfloxacin and ciprofloxacin),
and had a slightly elevated MIC of ceftazidime.
The amikacin MICs for resistant CF isolates
were 16–256 mg ⁄L (Table 3). MICs of other ami-
noglycosides were elevated, and most of these
isolates also showed resistance to fluoroquinolo-
nes, carbapenems and ceftazidime. The amikacin-
sensitive CF isolates were, with one exception,
susceptible to the antibiotics tested. MICs of
tetracycline showed only small variations
between mutants and clinical isolates.
Sequence analysis
DNA sequence analysis of mexZ and mexOZ
revealed that one (AK67) of ten laboratory
mutants had alterations in mexZ (deletion of four
Table 2. Summary of MICs (mg ⁄L), mutations in the regulatory gene mexZ and probable operator site (mexOZ), and
expression of mexZ, mexY (pump proteins) oprM and oprD (outer-membrane proteins) for PAO1 mutants
Strain ID AMK TOB NET GEN CAZ MEM IPM NOR CIP TET
Mutations Expression
mexZ mexOZ mexZ mexY mexB oprM oprD
PAO1 2 1 2 4 1 0.25 2 0.5 0.125 64 – – 1 1 1 1 1
AK66 8 2 16 4 2 2 4 0.5 0.0625 16 – – 10 8.2 2 0.2 2.02
AK3 8 1 8 4 1 0.25 2 0.5 0.125 16 – – 2.0 13 0.5 1.6 0.10
AK54 8 2 8 4 1 0.25 2 0.5 0.125 16 – – 1.5 14 0.5 0.6 0.06
AK38 8 1 2 4 1 0.5 2 0.5 0.125 16 – – 1.7 14 0.8 0 0.06
AK6 4 1 8 8 1 0.25 4 0.5 0.125 16 – – 1.7 15 0.3 0.4 0.04
AK4 4 1 4 4 1 0.5 2 0.5 0.125 16 – – 1.4 18 0.3 0.8 0.11
AK73 4 1 4 4 1 0.25 2 0.5 0.125 32 – – 2.1 21 0.5 0 0.08
AK76 64 4 32 8 1 0.5 2 1 0.125 32 – – 6 25 0.6 0.2 0.36
AK14 64 4 32 16 1 0.125 2 2 0.25 32 – – 3.3 44 0.3 0.2 0.05
AK67 64 4 32 16 4 4 8 8 2 32 DTTCA(233) C(215) ﬁ T 228 280 1.1 0.1 0.24
aAMK, amikacin; TOB, tobramycin; NET, netilmicin; GEN, gentamicin; CAZ, ceftazidine; MEM, meropenem; IPM, imipenem; NOR, norfloxacin; CIP, ciprofloxacin; TET,
tetracycline; D, deletion.
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nucleotides, TTCA, at positions 233–236) and a
single nucleotide change (C215 ﬁ T) in mexOZ.
This mutant had a multidrug-resistant phenotype.
No changes in mexZ and mexOZ were found in
the other mutants. In contrast, the sequence
analysis of clinical isolates (amikacin MICs
4–256 mg ⁄L) showed a number of different pat-
terns, such as single-base mutations, frameshifts
and deletions (Table 3). Isolate Cfz01 (amikacin
MIC 64 mg ⁄L) did not have any mutations in the
regions investigated. Isolate Cfz09 had the same
changes as found in mutant AK67 (Table 2).
Among the sensitive isolates, Cfz22 had muta-
tions in both mexZ and mexOZ, while Cfz13 had
an insertion of six nucleotides in mexZ.
Quantification of MexZ, MexY, MexB, OprM
and OprD mRNA
The relative levels of production of MexY, MexZ,
MexB, OprM and OprD cDNA compared to
PAO1 were calculated using RpsL cDNA as a
reference in real-time PCR analysis. Seven
mutants (amikacin MICs 4–8 mg ⁄L) produced 8–
21-fold more MexY mRNA than PAO1, and only
one (AK66) of these mutants produced more
MexZ mRNA than PAO1. Two mutants (AK76
and AK14) with high amikacin MICs (64 mg ⁄L)
produced 25- and 44-fold more MexY mRNA,
respectively, than PAO1, with a slightly elevated
amount of MexZ mRNA. Highly elevated levels
of MexY and MexZ mRNA were found in one
mutant (AK67), with mutations in the regulatory
region (Table 2); this mutant also showed higher
MICs of the other antibiotics tested, with the
exception of tetracycline. None of the mutants
had elevated levels of MexB or OprM mRNA. All
except two of the resistant CF isolates had a
higher amount of MexY mRNA (3.4–727-fold)
than PAO1 (Table 3), but there was no clear
correlation with mutations in the gene for the
regulatory protein or in the operator region. Most
CF isolates with elevated MexY mRNA were also
resistant to imipenem and meropenem. Isolates
Cfz08 and Cfz04 were resistant to amikacin, but
did not overproduce MexY mRNA. In contrast,
Table 3. Summary of MICs (mg ⁄L), mutations in the regulatory gene mexZ and probable operator site mexOZ, and
expression of mexZ, mexZ (pump protein), oprM and oprD (outer-membrane proteins) in strains from cystic fibrosis patients
Strain AMK TOB NET GEN CAZ MEM IPM NOR CIP TET
Mutations Expression
mexZ mexOZ mexZ mexY oprM oprD
Sensitive strains
PAO1 2 1 2 4 1 0.25 2 0.5 0.125 64 – – 1 1 1 1
Cfz21 4 1 4 2 2 0.125 2 0.5 0.125 128 – – 2.6 0.1 2.7 0.66
Cfz17 2 1 4 2 2 0.5 2 2 0.25 128 – – 2.4 0.4 11 1.9
Cfz18 1 1 1 0.5 1 0.0625 2 2 0.5 4 – – 1.5 0.7 1.6 0.34
Cfz22 2 1 4 2 1 0.125 0.5 8 4 64 Leu(CTG)4
ﬁ Pro(CCG)
A(42) ﬁ G
C(207) ﬁ T
4.7 1.6 0.2 0.02
Cfz13 4 1 4 2 0.5 0.0625 0.25 4 1 64 Insertiona – 3.8 58 1.7 12
Resistant strains
Cfz08 128 8 32 32 64 32 > 32 12 2 128 Leu(CTC)105
ﬁ Arg(CGA)
DG(39) 1.9 0.1 1.7 0.02
Cfz04 32 2 16 8 1 0.125 4 0.5 0.125 64 – Insertionb 2.3 2.5 0.4 0.005
Cfz26 16 2 8 4 16 4 32 8 2 8 Cys(TGC)80
ﬁ Arg(CGC)
– 7.6 3.4 41 0.68
Cfz03 32 4 32 32 > 256 32 > 32 32 8 32 DGT(205) – 1.3 36 5.5 0.03
Cfz06 64 4 32 16 256 > 32 > 32 16 4 32 Glu(GAA)116
ﬁ Lys(AAA)
– 0.6 55 1.3 0.01
Cfz15 64 4 32 16 8 32 > 32 8 4 32 Insertiona – 1.9 57 7.5 0.33
Cfz10 256 4 128 64 1 4 > 32 12 4 32 Arg(CGC)32
ﬁ Cys(TGC)
– 2.5 75 0.6 0.11
Cfz09 16 2 12 8 2 1 4 12 2 64 DTTCA(233) C(215) ﬁ T 7.4 77 0.2 2.32
Cfz14 128 4 128 32 256 > 32 > 32 2 0.5 64 Insertiona – 8.6 87 1.2 0.58
Cfz07 128 8 > 32 32 256 > 32 > 32 64 > 32 32 – A(178) ﬁ G 4.0 153 0.2 0.02
Cfz01 64 4 128 32 > 256 0.5 4 12 8 64 – – 0.7 185 1 0.09
Cfz16 64 2 32 8 > 256 > 32 > 32 16 8 32 Leu(CTG)4
ﬁ Pro(CCG)
– 4.4 209 7.1 0.66
Cfz12 128 8 128 64 2 0.25 0.5 16 8 32 – C(224) ﬁ T 3.1 258 1.9 0.03
Cfz05 128 8 128 32 4 0.5 4 2 0.5 64 Arg(CGC)159
ﬁ Pro(CCG)
– 1.5 325 0.2 0.22
Cfz02 64 4 64 16 > 256 > 32 > 32 2 1 32 Gln(CAG)107
ﬁ Pro(CCG)
Insertionc 2.1 727 2.4 0.02
Abbreviations as in Table 2.
aInsertion of six nucleotides, ACAAGA, at nucleotide positions 68–73, original frame restored.
bInsertion of G between nucleotides 195 and 196.
cInsertion of C between nucleotides 149 and 150.
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one amikacin-sensitive CF isolate, Cfz13, over-
produced MexY mRNA (58-fold compared with
PAO1). Significant overproduction of OprM
mRNA was found in only four CF isolates. All
mutants except one (AK66) produced less mRNA
for OprD than PAO1. Among the mutants, only
AK66 produced a higher amount of OprD mRNA,
while in clinical isolates its expression was eleva-
ted significantly in isolate Cfz13 (12-fold com-
pared with PAO1) and decreased in 11 of the
other clinical isolates.
Aminoglycoside-modifying enzymes
The clinical and mutant strains were tested by
PCR for genes encoding the aminoglycoside-
modifying enzymes that are most common in
P. aeruginosa. None were positive for the plasmid-
borne aminoglycoside-activating genes aac(6¢)-Ib
and ant(4¢)-IIb or the chromosomal aph(3¢)-IIps
gene.
DISCUSSION
The amikacin-resistant mutants of P. aeruginosa
divided into two groups, based on their amikacin
MIC (Table 2). The first group (AK66, AK3, AK54,
AK38, AK 6, AK4 and AK73) had slightly eleva-
ted amikacin MICs (1–2 dilution steps) and MexY
mRNA levels (8–21-fold) and, in six of these
mutants, there was no significant increase in
MexZ mRNA. The second group comprised three
mutants (AK14, AK76 and AK67) with high
amikacin MICs (64 mg ⁄L); one mutant (AK67)
from this group had the same mutations as a
clinical isolate (Cfz09). AK67 produced higher
levels of MexZ and MexY mRNA (200-fold) and
was more resistant to penems, fluoroquinolones
and ceftazidime. The MICs and mutations found
in this isolate indicate up-regulation of the mexXY
operon, probably in a similar way to the regula-
tion of the mexAB–oprM operon, where MexR
regulates the operon negatively and the operator
site for mexR and the gene mexA are located close
to each other [28,29]. The ratio of MexR and MexB
mRNA levels is close to one in MexAB-overpro-
ducing P. aeruginosa mutants (personal unpub-
lished results), as was the MexZ ⁄MexY mRNA
ratio in mutant AK67 (Table 2). Another type of
regulation must be present in the nine mutants
with no detectable changes in the regulatory
regions. Such systems have been described in
Escherichia coli [30], where a large number of
genes for antibiotic resistance are controlled by
global regulatory systems. There was a correlation
between the amount of MexY mRNA and the
level of resistance, and mutant AK67, which
produced the highest levels of mRNA, also
showed a multidrug resistance phenotype, in
agreement with the findings of Okamoto et al.
[22].
The MexXY efflux pump lacks an outer-mem-
brane protein of its own, and OprM can substitute
the missing function [20]. However, no evidence
was found for increased production of OprM; in
contrast, most mutants and some CF isolates had
OprM mRNA levels that were even lower than
those of PAO1. A few of the clinical isolates had
elevated OprM mRNA production, which may
be caused by over-expression ofmexAB–oprM. This
indicates that MexXY can also utilise outer-mem-
brane proteins other than OprM, such as OpmG,
OpmI, and OpmH [22,31]. Over-expression of
mexXY was not associated with altered expression
of mexAB–oprM [32], since MexB mRNA levels in
all mutants were similar to those of PAO1.
Decreased production of OprD affects susceptibil-
ity to carbapenems, but all mutants except AK66
produced less OprD mRNA than PAO1, without
any obvious effect on carbapenem MICs.
CF isolates (Table 3) showed a more complex
picture than the mutants, and some of the isolates
probably had more than one mechanism of
resistance to aminoglycosides. The wide variety
of base substitutions, deletions and insertions
found in mexZ and mexOZ could be a result of the
high frequency of hypermutable isolates in the CF
lung [33,34]. It is likely that MexXY plays a role in
aminoglycoside resistance in CF isolates and, in
some cases, may contribute to the multidrug
resistance phenotype. MexY mRNA was overpro-
duced in all except two of the amikacin-resistant
isolates (Cfz04 and Cfz08). However, one sensi-
tive isolate (Cfz13; MIC 4 mg ⁄L) also overpro-
duced MexY mRNA (58-fold), while another
susceptible isolate (Cfz22) had mutations without
overproduction of MexY. Possible explanations
may be that the cell wall of Cfz13 had increased
permeability to antibiotics, probably because of
over-expression of OprD, which negated the
effect of the efflux pump, as indicated by hyper-
susceptibility to imipenem and meropenem.
Another possibility is that alterations in the pump
protein in the substrate-binding region may have
Islam et al. MexXY and amikacin resistance in P. aeruginosa 881
 2004 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 10, 877–883
changed its specificity [14,35]. For some isolates,
in particular Cfz08 and Cfz04, which did not
overproduce MexY mRNA, other resistance
mechanisms, such as alterations in the ribosomal
binding sites for aminoglycosides, must be pre-
sent [36]. Commonly reported genes for amino-
glycoside-inactivating enzymes [37] were not
found in any of the CF strains, and such enzymes
are normally very rare among Swedish Pseudo-
monas isolates. The resistance patterns (high
MICs, mainly of amikacin and netilmicin) were
similar to those of the PAO1 mutants. Amikacin is
less susceptible to inactivating enzymes than
other aminoglycosides [38], although one 3¢-phos-
photransferase with high activity against amika-
cin has been described [27]. Tobramycin is
currently the standard treatment for Pseudomonas
infections in CF patients in Sweden, and amikacin
is used rarely.
In conclusion, overproduction of mRNA for the
MexXY efflux pump was found in 13 of 15
amikacin-resistant strains from CF patients and
in ten laboratory mutants. One of the mutants
with a high level of MexY mRNA had a multi-
drug resistance phenotype. The mexXY operon
appeared to be regulated either from mexZ or
from other gene(s), which remain to be character-
ised. Co-regulation with the MexAB–OprM efflux
pump was not found, but most mutants produced
less OprD mRNA, although this did not affect
susceptibility to carbapenems. However, possible
co-regulation of MexXY with an efflux pump with
aminoglycoside specificity or a membrane protein
could affect the MIC of amikacin.
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